drugset / Trial / NCT00820950

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

NCT00820950

Phase 2 Completed 29 enrolled Incyte Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.

Timeline

Start
2007-05-31
Primary completion
2009-01-31
Completion
2009-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule 0.005 % Topical
Subject Ruxolitinib Small molecule 0.5 % Topical
Subject Ruxolitinib Small molecule 1 % Topical
Subject Ruxolitinib Small molecule 1.5 % Topical
Subject betamethasone dipropionate Small molecule 0.05 % Topical

Indications